Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection
- PMID: 17597795
- DOI: 10.1038/sj.gt.3302958
Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection
Abstract
The CCR5 co-receptor is necessary for cellular entry by R5 tropic viral strains involved in primary HIV infection, but is dispensable for normal human physiology. Owing to its crucial role in HIV-1 infection, the CCR5 co-receptor has been the subject of many therapeutic approaches, including gene therapy. siRNA targeting was shown to be effective in downregulating CCR5 expression and conferring significant protection against HIV-1 in susceptible cells. However, complete knockdown of CCR5 expression has not been achieved and thus remains an elusive goal. In these studies, we identified new CCR5 siRNAs capable of achieving complete knockdown of the co-receptor expression. Our transfection studies have shown that longer 28-mer short hairpin siRNAs are very effective in gene downregulation as assessed by fluorescence-activated cell sorting and transcript quantitation by quantitative real-time polymerase chain reaction. These siRNAs conferred strong antiviral protection during viral challenge. To obtain stable expression, highly potent siRNA expression cassettes were introduced into lentiviral vectors. Similar high levels of CCR5 downregulation were observed in stably transduced cells with concomitant viral protection in cultured cell lines. To translate these results to a stem cell gene therapy setting, CD34 hematopoietic progenitor cells were transduced with lentiviral vectors to derive transgenic macrophages. The transgenic cells also exhibited high levels of CCR5 downregulation and viral resistance. With regard to Pol-III promoter-mediated siRNA expression, higher efficacies were obtained with U6-driven CCR5 siRNAs. However, in contrast to previous reports, no apparent cytotoxicities were observed in transgenic cells containing U6-driven siRNA constructs. Thus the above anti-CCR5 siRNAs are among the most effective demonstrated to date and are very promising candidates for clinical applications.
Similar articles
-
Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.Mol Ther. 2000 Mar;1(3):244-54. doi: 10.1006/mthe.2000.0038. Mol Ther. 2000. PMID: 10933940
-
Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.Gene Ther. 2005 Jul;12(14):1133-44. doi: 10.1038/sj.gt.3302509. Gene Ther. 2005. PMID: 15750613
-
Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.Gene Ther. 2002 Jul;9(13):889-97. doi: 10.1038/sj.gt.3301711. Gene Ther. 2002. PMID: 12080383
-
siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.Anticancer Res. 2003 May-Jun;23(3A):1997-2005. Anticancer Res. 2003. PMID: 12894572 Review.
-
RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.Ann N Y Acad Sci. 2006 Oct;1082:172-9. doi: 10.1196/annals.1348.006. Ann N Y Acad Sci. 2006. PMID: 17145937 Review.
Cited by
-
Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Int Rev Neurobiol. 2014;118:231-313. doi: 10.1016/B978-0-12-801284-0.00009-9. Int Rev Neurobiol. 2014. PMID: 25175867 Free PMC article. Review.
-
Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):152-61. doi: 10.1097/QAI.0b013e3181b010a0. J Acquir Immune Defic Syndr. 2009. PMID: 19593160 Free PMC article.
-
Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment.Int J Mol Sci. 2022 Nov 16;23(22):14159. doi: 10.3390/ijms232214159. Int J Mol Sci. 2022. PMID: 36430633 Free PMC article. Review.
-
Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression.Hum Gene Ther. 2012 May;23(5):521-32. doi: 10.1089/hum.2011.145. Epub 2012 Mar 9. Hum Gene Ther. 2012. PMID: 22229698 Free PMC article.
-
Therapeutic genome mutagenesis using synthetic donor DNA and triplex-forming molecules.Methods Mol Biol. 2015;1239:39-73. doi: 10.1007/978-1-4939-1862-1_4. Methods Mol Biol. 2015. PMID: 25408401 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous